DeepSeek to Raise AI API Prices as Demand for New Models Surges 
Western Digital Q4 Earnings Beat Estimates as FY2027 Outlook Tops Expectations 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Nvidia Seen Beating Q2 Targets as Vera Rubin Cycle Begins 
SanDisk Q4 Earnings Beat Estimates as Q1 Revenue Outlook Meets Expectations 
Heineken H1 Operating Profit Meets Forecast as Beer Volumes Beat Expectations 
DBS Raises 2025 Outlook After Record Q2 Profit Driven by Wealth Management 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Meta Ordered to Pay $567M Over Child Safety Violations in New Mexico 
Alibaba Plans Revenue-Sharing Model for Qwen3.8-Max AI Commercial Users 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
Sinopec Boosts Russian ESPO Oil Purchases as Middle East Supply Tightens 
Nvidia to Invest Up to $3 Billion in Blackstone-Backed Lancium 
Glencore Posts Strong H1 2026 Earnings, Announces ASX Secondary Listing 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
SEATTLE, Feb. 27, 2018 -- Aptevo Therapeutics Inc. (Nasdaq:APVO), a biotechnology company focused on developing novel oncology and hematology therapeutics, today announced that management will be presenting at the 30th Annual ROTH Conference on Tuesday March 13th, 2018 at 12:00 p.m. PT at the Ritz Carlton, Laguna Niguel, California.
A live audio webcast of the presentation can be accessed at www.aptevotherapeutics.com under the ‘Investors’ section of the website, under ‘Events.’ An audio reply of the webcast will be available following the live webcast.
About Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on novel oncology and hematology therapeutics to meaningfully improve patients’ lives. Aptevo has a commercial product, IXINITY® coagulation factor IX (recombinant), approved and marketed in the United States for the treatment of Hemophilia B, and a versatile core technology – the ADAPTIR™ modular protein technology platform capable of generating highly-differentiated bispecific antibodies with unique mechanisms of action to treat cancer or autoimmune diseases. Aptevo has two ADAPTIR antibody candidates currently in clinical development and a broad pipeline of novel investigational-stage bispecific antibody candidates focused in immuno-oncology and autoimmune disease and inflammation. For more information, please visit www.aptevotherapeutics.com
Source:
Aptevo Therapeutics
Stacey Jurchison
Senior Director, Investor Relations and Corporate Communications
206-859-6628
[email protected]
